ABSTRACT | Residual cyst is an inflammatory odontogenic cyst resultant from pulp necrosis, where the tooth has already been removed. Bisphosphonates are drugs used in the prevention and treatment of bone metabolism diseases with intense resorption activity, and they have been associated with osteonecrosis of the jaws, an important side effect. The aim of this study was to report a successful surgical treatment of a residual cyst in a patient who had previously developed jaw osteonecrosis associated with sodium alendronate use. We emphasize here the importance of safe preoperative procedures when approaching these patients.
INTRODUCTION
Bisphosphonates are a group of drugs that have been used in the management of metabolic and oncologic diseases characterized by an increase of osteoclastic activity. In the clinical setting, these agents are available for oral and intravenous (IV) administration. 1 The first one is primarily used for treatment of osteoporosis, reducing the risk of vertebral and non-vertebral fractures. When administered by IV route, they are indicated for stabilization of bone metastasis of solid tumors, treatment of bone resorption defects in multiple myeloma, correction of hypercalcemia and in the management of Paget's disease and fibrous dysplasia. 1 The aim of this study is to report a successful surgical treatment of a maxillary residual cyst in a patient who had previously developed BRONJ associated with alendronate use. Bisphosphonates are able to interfere with remodeling of bone tissue by acting on different cells. 8, 9 Their effect on osteoclasts occurs by inhibiting recruitment and differentiation, decreasing life span and promoting apoptosis. The presence of numerous bacteria, especially Actinomyces sp., in MRONJ lesions has been reported. 8 Other effects of these drugs, such as impairment of both angiogenesis and epithelial cell proliferation, 9 support the hypothesis that osteonecrosis of the jaws has a multifactorial etiology.
CASE REPORT
Despite controversies, Ruggiero et al. Moreover, although rare, MRONJ associated with oral bisphosphonate does happen. Therefore, the correct approaching of the patient can provide a safe procedure avoiding MRONJ occurrence. Also, the need for identifying treatment protocols capable of reducing the incidence of this oral disease is ever more pressing.
